Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for QIAGEN N.V. (QGEN : NYSE)
 
 • Company Description   
QIAGEN N.V. is one of the world's leading providers of technologies and products for the separation, purification and handling of nucleic acids DNA/RNA. The company provides innovative technologies and products for pre-analytical sample preparation and molecular diagnostics solutions. It has developed a comprehensive portfolio of proprietary, consumable products, and automated solutions for sample collection. Qiagen has subsidiaries several other countries with good sales potential. Segment Details Consumables: These are typically sample preparation or test kits that contain all the necessary reagents and buffers, and a manual including protocols and relevant background information. Automated Instruments: These automate the use of Sample & Assay Technologies into efficient solutions for a broad range of laboratory needs. Customer Classes: QIAGEN focuses on 4 principal segments or customer classes for sample and assay technologies:? Molecular Diagnostics, Applied Testing, Pharma and Academia.

Number of Employees: 5,654

 
 • Price / Volume Information   
Yesterday's Closing Price: $43.47 Daily Weekly Monthly
20 Day Moving Average: 2,987,770 shares
Shares Outstanding: 206.07 (millions)
Market Capitalization: $8,958.07 (millions)
Beta: 0.63
52 Week High: $57.82
52 Week Low: $32.53
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -0.87% -0.42%
12 Week 17.45% 14.95%
Year To Date -8.17% -18.56%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
HULSTERWEG 82
-
PL VENLO,P7 5912
NLD
ph: 31-77-355-6600
fax: 31-77-355-6658
daniel.wendorff@qiagen.com http://www.qiagen.com
 
 • General Corporate Information   
Officers
Thierry Bernard - Chief Executive Officer
Roland Sackers - Chief Financial Officer
Toralf Haag - Supervisory Director
Eva Pisa - Supervisory Director
Metin Colpan - Supervisory Director

Peer Information
QIAGEN N.V. (CORR.)
QIAGEN N.V. (RSPI)
QIAGEN N.V. (CGXP)
QIAGEN N.V. (BGEN)
QIAGEN N.V. (GTBP)
QIAGEN N.V. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: N72482156
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 06/01/26
Next Expected EPS Date: 11/03/26
Share - Related Items
Shares Outstanding: 206.07
Most Recent Split Date: 1.00 (0.95:1)
Beta: 0.63
Market Capitalization: $8,958.07 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.81%
Current Fiscal Quarter EPS Consensus Estimate: $0.62 Indicated Annual Dividend: $0.35
Current Fiscal Year EPS Consensus Estimate: $2.43 Payout Ratio: 0.11
Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio: 0.09
Estmated Long-Term EPS Growth Rate: 4.13% Last Dividend Paid: 07/07/2026 - $0.35
Next EPS Report Date: 11/03/26  
 

 • Fundamental Ratios
P/E
Current FY Estimate: 17.88
Trailing 12 Months: 17.95
PEG Ratio: 4.33
Price Ratios
Price/Book: 2.67
Price/Cash Flow: 12.77
Price / Sales: 4.27
EPS Growth
vs. Year Ago Period: -1.83%
vs. Previous Quarter: 14.81%
Sales Growth
vs. Year Ago Period: 0.28%
vs. Previous Quarter: 8.68%
ROE
06/30/26 - 14.47
03/31/26 - 14.40
12/31/25 - 14.56
ROA
06/30/26 - 8.34
03/31/26 - 8.40
12/31/25 - 8.62
Current Ratio
06/30/26 - 2.85
03/31/26 - 3.21
12/31/25 - 3.90
Quick Ratio
06/30/26 - 2.31
03/31/26 - 2.57
12/31/25 - 3.31
Operating Margin
06/30/26 - 24.32
03/31/26 - 24.47
12/31/25 - 24.97
Net Margin
06/30/26 - 19.49
03/31/26 - 19.16
12/31/25 - 20.33
Pre-Tax Margin
06/30/26 - 21.99
03/31/26 - 21.75
12/31/25 - 23.46
Book Value
06/30/26 - 16.29
03/31/26 - 16.17
12/31/25 - 17.89
Inventory Turnover
06/30/26 - 2.62
03/31/26 - 2.67
12/31/25 - 2.71
Debt-to-Equity
06/30/26 - 0.48
03/31/26 - 0.49
12/31/25 - 0.44
Debt-to-Capital
06/30/26 - 32.64
03/31/26 - 33.08
12/31/25 - 30.45
 

Powered by Zacks Investment Research ©